AI, Machine Learning & Computational Biology
STAT+: Democrats prepare for health care overhaul
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Chelsea Handler had a lot to say about the “most toxic” home she bought from RFK Jr. and Cheryl Hines for nearly $6 million. Don’t forget to check out STAT’s Breakthrough Summit East today, and send new tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
Rising from the ashes
Democrats say Republicans have set health care so far back that they have an opportunity to remake it from scratch.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Chelsea Handler had a lot to say about the “most toxic” home she bought from RFK Jr. and Cheryl Hines for nearly $6 million. Don’t forget to check out STAT’s Breakthrough Summit East today, and send new tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
Rising from the ashes
Democrats say Republicans have set health care so far back that they have an opportunity to remake it from scratch.
AI, Machine Learning & Computational Biology
AI is changing the talent biotech companies compete to hire
As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine learning, data and engineering. Recruiting expert Darren Nelson explains which capabilities are becoming hardest to find—and why.
AI, Machine Learning & Computational Biology
Consolidating Antibody Discovery Data with an AI Platform
The Sapio Scientific AI platform gives scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.
The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN – Genetic Engineering and Biotechnology News.
FairJourney Bio (FJBio) selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions to replace spreadsheet-based records and manual reporting processes across its international operations.
FJBio is a global antibody discovery and engineering partner. Founded in 2012, the company works on taking programs from target to preclinical candidate within a single integrated workflow, run by one team across three centers of excellence: Porto (Portugal), Cambridge (U.K.), and San Diego (U.S.). The antibody company completed more than 1,400 programs for over 250 industry partners across pharma, biotech, and academia, with 20 partner assets in clinical trials.
The volume and complexity of experimental data generated across those programs made consistent, structured records a scientific and operational priority for FJBio, according to Sapio Sciences’ CCO Mike Hampton, who added that the company’s AI platform will serve as the informatics backbone across all of FJBio’s discovery and cell sciences operations.
Provides a single entity registry
Sapio’s ELN solution will record experimental data across phage display, screening, and cell sciences programs, replacing the need for scientists to capture data on paper templates before manually re-entering results into spreadsheets. As FJBio’s program portfolio has grown across three sites, the Sapio LIMS gives the company a single entity registry, from target registration through clone identification and screening results, searchable across programs, points out Hampton.
The solution is also designed to ensure integration of lab instruments, connecting instrument output directly to Sapio’s experiment records and eliminating manual data transcription at the bench. Structured client data reports, that were assembled by hand from individual experiment records will now come straight out of the platform, expected to return up to 40% of scientific staff time back to discovery, says a Sapio spokesperson.
“FairJourney Bio runs discovery programs of genuine depth and complexity across multiple international sites,” comments the spokesperson. “The Sapio Scientific AI platform gives their scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.”

“As our operations have grown across three international sites, we needed an informatics platform that could keep pace with that responsibility,” says Vidal. “The Sapio Platform gives our scientists a single connected environment for every experiment, every sample and every result, and it holds that data to the integrity and security standards our clients expect.”
Elain brings intelligence directly into FJBio’s scientific workflows, says Hampton. Working across the structured experimental data held within the Sapio Platform, Elain enables scientists to interact with their data using natural language, without leaving the environment where their experiments, samples and results are managed, he explains.
The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN - Genetic Engineering and Biotechnology News.
AI, Machine Learning & Computational Biology
AI automates 3D membrane mapping, matching manual results in a fraction of time
Cell membranes and the proteins within them control many vital processes and play a key role in health and disease. But studying them in 3D images of cells has so far meant slow, manual work. A team from Helmholtz Munich, the Technical University of Mu…
-
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Nature Biotechnology6 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Uncategorized5 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized4 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
STAT News – Biotech6 months agoSTAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
-
Nature Biotechnology6 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read